Abstract 2124P
Background
Malnutrition affects up to 75% of cancer pts and results from a combination of anorexia and metabolic dysregulation. Metabolic and nutritional abnormalities in cancer pts can lead to cachexia, a multifactorial syndrome characterized by involuntary loss of skeletal muscle mass, systemic inflammation and increased protein catabolism. Cancer cachexia negatively affects patients’ outcomes, compliance to anticancer treatments, quality of life and survival. However, risk of malnutrition and cachexia are still under recognized in cancer pts. The Prevalence of Malnutrition in Oncology (PreMiO) study revealed that 51% of pts had nutritional impairment already at the first medical oncology visit.
Methods
The retrospective, observational NUTRIONCO study included a subpopulation (n=571 pts) of the prospective, observational PREMiO study (n=1952 pts) for whom follow-up data were collected from August 2019 to October 2021 and made available in electronic case report forms at ten medical oncology sites in Italy. The clinical outcomes that were considered for the association analysis with the baseline clinical and nutritional variables were: patient’s rehospitalization, onset of treatment-related toxicity, patient’s death and disease progression.
Results
We highlighted a statistically significant association between baseline variables and patients’ death, rehospitalization, treatment toxicity and disease progression at follow-up. We found a higher overall survival probability in well-nourished general study population vs. malnourished pts (p<0.001). Patients’ stratification revealed that malnutrition decreased the survival probability in non-metastatic pts, but not in metastatic pts (p<0.001). Multivariate analysis confirmed that baseline malnutrition (p=0.004) and VAS score for appetite loss (p=0.0104), in addition to albumin <35 g/L (p<0.0001) and neutrophil/lymphocyte ratio >3 (p=0.0007), were independently associated with death of non-metastatic pts at follow-up.
Conclusions
These findings support the importance of a proactive, early management of malnutrition and cachexia in cancer pts, and in particular in non-metastatic pts, in the perspective of a substantial improvement of their clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AIOM Foundantion.
Funding
Fresenius-Kabi Italy.
Disclosure
A. Frassoldati: Financial Interests, Personal, Advisory Role: Roche, Novartis, Pfizer, Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06